SLS

SELLAS Life Sciences Group, Inc.

Price Chart

Latest Quote

$8.05

+0.29 (+3.74%)

Current Price

Previous Close	$7.76
Open	$8.00
Day High	$8.38
Day Low	$7.91
Volume	14,689,578

Fetched: 2026-06-19T18:36:15

Stock Information

Shares Outstanding	196.63M
Total Debt	$871K
Cash Equivalents	$107.10M
Net Income	$-29.46M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.58B
EPS (TTM)	$-0.23
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.29B
Income	$-29.46M
Book/sh	$0.59
Cash/sh	$0.54
Employees	13

Financial Ratios

Quick Ratio	16.59
Current Ratio	17.22
Debt/Eq	0.81

Returns & Margins

ROA	-25.45%
ROE	-43.59%

Ownership

Insider Ownership	0.41%
Institutional Ownership	27.62%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-53.67
P/B	13.60

Analyst Data

Recommendation	none
Target Price	$10.00

Technical Indicators

SMA20	$8.14
SMA50	$6.52
SMA200	$3.90
RSI	38.25
ATR	0.6779

Shares Float	185.23M
Short Float	32.93%
Short Ratio	6.06
Volatility	2.53
Rel Volume	1.55

Performance History

Week	+3.87%
Month	+6.06%
Quarter	+54.81%
6 Months	+265.91%
YTD	+85.06%
Year	+416.03%
3 Years	+387.88%
5 Years	-29.57%
10 Years	-99.99%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$8.05	14,747,800
2026-06-17	$7.76	4,681,700
2026-06-16	$7.53	4,289,500
2026-06-15	$7.73	5,860,900
2026-06-12	$7.83	4,060,200
2026-06-11	$7.75	6,271,500
2026-06-10	$7.15	6,681,100
2026-06-09	$7.68	6,924,800
2026-06-08	$7.98	5,887,200
2026-06-05	$8.23	6,725,500
2026-06-04	$9.04	8,435,800
2026-06-03	$8.19	7,546,200
2026-06-02	$8.33	10,354,600
2026-06-01	$9.07	7,363,200
2026-05-29	$9.31	25,866,500
2026-05-28	$9.18	10,305,200
2026-05-27	$8.58	9,211,400
2026-05-26	$8.12	8,743,400
2026-05-22	$7.78	10,694,200
2026-05-21	$7.56	25,118,400
2026-05-20	$8.97	18,441,700
2026-05-19	$7.59	7,882,400

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

📰 Latest News

All Eyes On SLS Stock Ahead Of Annual Shareholder Meet – What’s On The Agenda?

Stocktwits • 2026-06-16T15:09:07Z

Exploring 3 High Growth Tech Stocks in US Market

Simply Wall St. • 2026-06-15T11:39:04Z

SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute

Stocktwits • 2026-06-05T08:51:34Z

SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers

Stocktwits • 2026-06-02T14:54:25Z

Jim Cramer on SELLAS: “It’s a Great Spec”

Insider Monkey • 2026-06-01T17:33:03Z

SELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer Endorsement

Simply Wall St. • 2026-05-29T20:02:46Z

SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout

Stocktwits • 2026-05-29T04:40:32Z

SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS

Stocktwits • 2026-05-28T03:30:00Z

SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms

Stocktwits • 2026-05-27T03:21:02Z

SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout

Stocktwits • 2026-05-26T11:26:18Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$1,000,000
Operating Revenue	$0	$0	$0	$1,000,000
Reconciled Cost Of Revenue	-	-	$0	$100,000
Cost Of Revenue	-	-	$0	$100,000
Expenses
Total Expenses	$28,274,000	$31,513,000	$37,869,000	$32,950,000
Net Non Operating Interest Income Expense	$1,411,000	$632,000	$525,000	$317,000
Operating Expense	$28,274,000	$31,513,000	$37,869,000	$32,850,000
General And Administrative Expense	$12,252,000	$12,417,000	$13,862,000	$12,582,000
Other Income Expense	-	-	$4,000	$-9,668,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Interest Income	$1,411,000	$632,000	$525,000	$317,000
Interest Income	$1,411,000	$632,000	$525,000	$317,000
Normalized Income	$-26,863,000	$-30,881,000	$-37,344,000	$-31,633,000
Net Income From Continuing And Discontinued Operation	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Total Operating Income As Reported	$-28,274,000	$-31,513,000	$-37,869,000	$-41,950,000
Net Income Common Stockholders	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Income	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Income Including Noncontrolling Interests	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Income Continuous Operations	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Pretax Income	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Interest Income Non Operating	$1,411,000	$632,000	$525,000	$317,000
Operating Income	$-28,274,000	$-31,513,000	$-37,869,000	$-31,950,000
Special Income Charges	-	-	$0	$-9,704,000
Gross Profit	-	-	$0	$900,000
Per Share
Diluted EPS	$-0.25	$-0.50	$-1.34	$-2.13
Basic EPS	$-0.25	$-0.50	$-1.34	$-2.13
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-28,274,000	$-31,513,000	$-37,873,000	$-22,282,000
EBITDA (Bullshit earnings)	$-28,274,000	$-31,513,000	$-37,869,000	$-31,950,000
EBIT	$-28,274,000	$-31,513,000	$-37,869,000	$-31,950,000
Diluted Average Shares	$109,051,215	$61,202,412	$27,777,111	$19,395,709
Basic Average Shares	$109,051,215	$61,202,412	$27,777,111	$19,395,709
Diluted NI Availto Com Stockholders	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Research And Development	$16,022,000	$19,096,000	$24,007,000	$20,268,000
Selling General And Administration	$12,252,000	$12,417,000	$13,862,000	$12,582,000
Other Gand A	$12,252,000	$12,417,000	$13,862,000	$12,582,000
Total Unusual Items	-	-	$4,000	$-9,668,000
Total Unusual Items Excluding Goodwill	-	-	$4,000	$-9,668,000
Restructuring And Mergern Acquisition	-	-	$0	$-296,000
Gain On Sale Of Security	-	-	$4,000	$36,000
Tax Provision	-	-	-	$0
Other Special Charges	-	-	-	$10,000,000
Impairment Of Capital Assets	-	-	-	$0
Otherunder Preferred Stock Dividend	-	-	-	-

Fetched: 2026-06-18

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$68,957,000	$7,551,000	$-9,890,000	$2,937,000
Total Assets	$78,345,000	$19,432,000	$6,219,000	$20,943,000
Total Non Current Assets	$3,134,000	$3,105,000	$3,047,000	$3,187,000
Other Non Current Assets	$257,000	$266,000	$275,000	$399,000
Goodwill And Other Intangible Assets	$1,914,000	$1,914,000	$1,914,000	$1,914,000
Current Assets	$75,211,000	$16,327,000	$3,172,000	$17,756,000
Other Current Assets	$223,000	-	-	$46,000
Restricted Cash	$100,000	$100,000	$100,000	$100,000
Prepaid Assets	$3,095,000	$2,341,000	$542,000	$485,000
Cash Cash Equivalents And Short Term Investments	$71,793,000	$13,886,000	$2,530,000	$17,125,000
Cash And Cash Equivalents	$71,793,000	$13,886,000	$2,530,000	$17,125,000
Non Current Prepaid Assets	-	-	-	$399,000
Receivables	-	-	-	-
Debt
Total Debt	$1,001,000	$1,001,000	$906,000	$945,000
Long Term Debt And Capital Lease Obligation	$457,000	$457,000	$460,000	$573,000
Current Debt And Capital Lease Obligation	$544,000	$544,000	$446,000	$372,000
Liabilities
Total Liabilities Net Minority Interest	$7,474,000	$9,967,000	$14,195,000	$16,092,000
Total Non Current Liabilities Net Minority Interest	$457,000	$457,000	$460,000	$577,000
Current Liabilities	$7,017,000	$9,510,000	$13,735,000	$15,515,000
Other Current Liabilities	$42,000	$42,000	$42,000	-
Payables And Accrued Expenses	$4,678,000	$7,147,000	$11,754,000	$13,704,000
Payables	$2,948,000	$3,500,000	$5,639,000	$8,857,000
Accounts Payable	$2,948,000	$3,500,000	$5,639,000	$3,357,000
Derivative Product Liabilities	-	-	$0	$4,000
Other Payable	-	-	-	$5,500,000
Other Non Current Liabilities	-	-	-	-
Non Current Deferred Liabilities	-	-	-	-
Non Current Deferred Taxes Liabilities	-	-	-	-
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Total Equity Gross Minority Interest	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Stockholders Equity	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Retained Earnings	$-274,988,000	$-248,125,000	$-217,244,000	$-179,904,000
Other
Ordinary Shares Number	$153,103,459	$73,977,459	$32,132,890	$21,005,405
Share Issued	$153,103,459	$73,977,459	$32,132,890	$21,005,405
Tangible Book Value	$68,957,000	$7,551,000	$-9,890,000	$2,937,000
Invested Capital	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Working Capital	$68,194,000	$6,817,000	$-10,563,000	$2,241,000
Capital Lease Obligations	$1,001,000	$1,001,000	$906,000	$945,000
Total Capitalization	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Additional Paid In Capital	$345,844,000	$257,583,000	$209,265,000	$184,753,000
Capital Stock	$15,000	$7,000	$3,000	$2,000
Common Stock	$15,000	$7,000	$3,000	$2,000
Long Term Capital Lease Obligation	$457,000	$457,000	$460,000	$573,000
Current Capital Lease Obligation	$544,000	$544,000	$446,000	$372,000
Pensionand Other Post Retirement Benefit Plans Current	$1,753,000	$1,777,000	$1,493,000	$1,439,000
Current Accrued Expenses	$1,730,000	$3,647,000	$6,115,000	$4,847,000
Goodwill	$1,914,000	$1,914,000	$1,914,000	$1,914,000
Net PPE	$963,000	$925,000	$858,000	$874,000
Gross PPE	$963,000	$925,000	$858,000	$874,000
Other Properties	$963,000	$925,000	$858,000	$874,000
Preferred Stock	-	-	$0	$0
Current Deferred Revenue	-	-	-	-

Fetched: 2026-06-18

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-28,389,000	$-35,402,000	$-36,910,000	$-28,309,000
Operating Activities
Operating Cash Flow	$-28,389,000	$-35,402,000	$-31,410,000	$-23,809,000
Cash Flow From Continuing Operating Activities	$-28,389,000	$-35,402,000	$-31,410,000	$-23,809,000
Operating Gains Losses	-	-	$-4,000	$-36,000
Investing Activities
Investing Cash Flow	-	$0	$-5,500,000	$-4,500,000
Cash Flow From Continuing Investing Activities	-	$0	$-5,500,000	$-4,500,000
Capital Expenditure	-	-	$-5,500,000	$-4,500,000
Financing Activities
Issuance Of Capital Stock	$23,051,000	$46,164,000	$22,225,000	$23,994,000
Financing Cash Flow	$86,296,000	$46,758,000	$22,315,000	$24,079,000
Cash Flow From Continuing Financing Activities	$86,296,000	$46,758,000	$22,315,000	$24,079,000
Net Other Financing Charges	$-527,000	$-64,000	$-31,000	-
Net Common Stock Issuance	$23,051,000	$46,164,000	$22,225,000	$23,994,000
Common Stock Issuance	$23,051,000	$46,164,000	$22,225,000	$23,994,000
Other
End Cash Position	$71,893,000	$13,986,000	$2,630,000	$17,225,000
Beginning Cash Position	$13,986,000	$2,630,000	$17,225,000	$21,455,000
Changes In Cash	$57,907,000	$11,356,000	$-14,595,000	$-4,230,000
Proceeds From Stock Option Exercised	$63,772,000	$658,000	$121,000	$85,000
Change In Working Capital	$-4,079,000	$-6,646,000	$3,345,000	$5,641,000
Change In Other Current Liabilities	$-635,000	$-533,000	$-518,000	$-471,000
Change In Payables And Accrued Expense	$-2,476,000	$-4,323,000	$3,750,000	$4,859,000
Change In Accrued Expense	$-1,941,000	$-2,184,000	$1,449,000	$3,646,000
Change In Payable	$-535,000	$-2,139,000	$2,301,000	$1,213,000
Change In Account Payable	$-535,000	$-2,139,000	$2,301,000	$1,213,000
Change In Prepaid Assets	$-968,000	$-1,790,000	$113,000	$1,253,000
Other Non Cash Items	$597,000	$561,000	$495,000	$10,161,000
Stock Based Compensation	$1,956,000	$1,564,000	$2,094,000	$1,726,000
Net Income From Continuing Operations	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Intangibles Purchase And Sale	-	$0	$-5,500,000	$-4,500,000
Purchase Of Intangibles	-	$0	$-5,500,000	$-4,500,000
Gain Loss On Investment Securities	-	-	$-4,000	$-36,000
Change In Receivables	-	-	-	$0
Asset Impairment Charge	-	-	-	$0
Deferred Tax	-	-	-	$0
Deferred Income Tax	-	-	-	$0
Change In Other Working Capital	-	-	-	-

Fetched: 2026-06-18